Multi-organ Imaging of Microvascular and Metabolic Function

Status

Not yet recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT07604207

Enrollment

Registered

2026-05-22

Start date

2026-07-01

Completion date

2031-07-01

Last updated

2026-05-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiovascular Diseases (CVD), Healthy Subjects (HS)

Brief summary

What if heart disease starts outside the heart? This research will study how to simultaneously assess brain and body physiology, how they are jointly related to heart function, and how their response to physical and mental stress differs in patients with heart disease.

Interventions

DRUG18F-FDG

Dynamic 18F-FDG PET

DEVICEPositron Emission Tomography (PET)

Panorama GS PET/CT

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

BASIC_SCIENCE

Masking

NONE

Intervention model description

Participants will undergo PET/CT scan(s) at rest and under a physical or mental stimuli

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* Adults aged 18 years and older * For patients with cardiovascular disease: Documented diagnosis of ischemic heart disease based on standard clinical, radiologic, and/or histopathologic criteria, as documented in the medical record; or a clinical nuclear cardiac stress PET test within 1 year. * For healthy subjects: No diagnosis of cardiometabolic disease, cancer, or other major disease within the past 5 years

Exclusion criteria

* Contraindications to PET due to: 1. Research-related radiation exposure exceeding current MGB Radiology Department guidelines (i.e., 50 mSv in the prior 12 months); 2. Inability to lie comfortably on the bed inside the scanner; 3. Body weight \> 300 lbs (weight limit of the scanner table); 4. Pregnancy or breastfeeding; * Individuals with fasting plasma glucose level of \>200 mg/dL; * Claustrophobia * Employed under the direct supervision of the PI conducting the research.

Design outcomes

Primary

Measure	Time frame	Description
Blood flow responses	During the procedure	The primary endpoint is to evaluate if blood flow responses to acute stressors can be quantitatively measured with 18F-FDG

Secondary

Measure	Time frame	Description
Glucose metabolism responses	During the scan	The secondary endpoint is to evaluate if glucose metabolic responses to acute stressors can be quantitatively measured with 18F-FDG

Contacts

CONTACTKevin J. Chung, PhD

kchung0@mgh.harvard.edu617-724-9232

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 23, 2026